143 related articles for article (PubMed ID: 32533632)
21. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
Roberts P
Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
[TBL] [Abstract][Full Text] [Related]
22. The effect of a non-denaturing detergent and a guanidinium-based inactivation agent on the viability of Ebola virus in mock clinical serum samples.
Burton JE; Easterbrook L; Pitman J; Anderson D; Roddy S; Bailey D; Vipond R; Bruce CB; Roberts AD
J Virol Methods; 2017 Dec; 250():34-40. PubMed ID: 28941617
[TBL] [Abstract][Full Text] [Related]
23. On-column virus inactivation by solvent/detergent treatment for a recombinant biological product.
Polasek D; Flicker A; Fiedler C; Farcet MR; Purtscher M; Kreil TR
Biologicals; 2023 Aug; 83():101693. PubMed ID: 37516085
[TBL] [Abstract][Full Text] [Related]
24. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
25. Enveloped virus inactivation using neutral arginine solutions and applications in therapeutic protein purification processes.
McCue JT; Selvitelli K; Cecchini D; Brown R
Biotechnol Prog; 2014; 30(1):108-12. PubMed ID: 24124172
[TBL] [Abstract][Full Text] [Related]
26. TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus.
Chou ML; Burnouf T; Chang SP; Hung TC; Lin CC; Richardson CD; Lin LT
PLoS One; 2015; 10(2):e0117800. PubMed ID: 25658612
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of Blood-Borne Enveloped Viruses with the Nonionic Detergent 2-[4-(2,4,4-Trimethylpentan-2-yl)Phenoxy]Ethanol Does Not Bias Clinical Chemistry Results.
Bailey AL; Farnsworth C
J Appl Lab Med; 2021 Sep; 6(5):1123-1132. PubMed ID: 33993264
[TBL] [Abstract][Full Text] [Related]
28. Effective chemical virus inactivation of patient serum compatible with accurate serodiagnosis of infections.
Remy MM; Alfter M; Chiem MN; Barbani MT; Engler OB; Suter-Riniker F
Clin Microbiol Infect; 2019 Jul; 25(7):907.e7-907.e12. PubMed ID: 30391583
[TBL] [Abstract][Full Text] [Related]
29. Characterization of operating parameters for XMuLV inactivation by low pH treatment.
Chinniah S; Hinckley P; Connell-Crowley L
Biotechnol Prog; 2016; 32(1):89-97. PubMed ID: 26488618
[TBL] [Abstract][Full Text] [Related]
30. Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.
Seitz H; Blümel J; Schmidt I; Willkommen H; Löwer J
Biologicals; 2002 Sep; 30(3):197-205. PubMed ID: 12217344
[TBL] [Abstract][Full Text] [Related]
31. Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate.
Burnouf T; Chou ML; Cheng LH; Li ZR; Wu YW; El-Ekiaby M; Tsai KH
Vox Sang; 2013 Jan; 104(1):1-6. PubMed ID: 22758375
[TBL] [Abstract][Full Text] [Related]
32. Inactivation strategy for pseudorabies virus in milk for production of biopharmaceuticals.
Chang JT; Chou YC; Lin MS; Wang SR
Jpn J Vet Res; 2010 Nov; 58(3-4):179-83. PubMed ID: 21180258
[TBL] [Abstract][Full Text] [Related]
33. Characterization of ionic strength for X-MuLV inactivation by low pH treatment for monoclonal antibody purification.
Daya J; Cusick V; Mattila J
Biotechnol Bioeng; 2023 Jun; 120(6):1605-1613. PubMed ID: 36924035
[TBL] [Abstract][Full Text] [Related]
34. Influence of detergents on the function of cloned potassium channels.
Höllerer-Beitz G; Heinemann SH
Recept Channels; 1998; 5(2):61-78. PubMed ID: 9606711
[TBL] [Abstract][Full Text] [Related]
35. Large-scale purification of high purity α1-antitrypsin from Cohn Fraction IV with virus inactivation by solvent/detergent and dry-heat treatment.
Huangfu C; Zhang J; Ma Y; Jia J; Li J; Lv M; Ma X; Zhao X; Zhang J
Biotechnol Appl Biochem; 2018 May; 65(3):446-454. PubMed ID: 29072333
[TBL] [Abstract][Full Text] [Related]
36. Orthogonal inactivation of influenza and the creation of detergent resistant viral aggregates: towards a novel vaccine strategy.
Belanger JM; Raviv Y; Viard M; Baxa U; Blumenthal R
Virol J; 2012 Mar; 9():72. PubMed ID: 22449007
[TBL] [Abstract][Full Text] [Related]
37. Inactivation of viruses using novel protein A wash buffers.
Bolton GR; Selvitelli KR; Iliescu I; Cecchini DJ
Biotechnol Prog; 2015; 31(2):406-13. PubMed ID: 25482293
[TBL] [Abstract][Full Text] [Related]
38. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.
Remington KM; Trejo SR; Buczynski G; Li H; Osheroff WP; Brown JP; Renfrow H; Reynolds R; Pifat DY
Vox Sang; 2004 Jul; 87(1):10-8. PubMed ID: 15260817
[TBL] [Abstract][Full Text] [Related]
39. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Transfusion; 2006 Dec; 46(12):2100-8. PubMed ID: 17176321
[TBL] [Abstract][Full Text] [Related]
40. A feasibility study on the effects of Triton X-100 for the in vitro inactivation of Ebola virus on haematological assays.
Mifsud A; Peelen D; Brincat P; Abela S; Debattista N; Laspina S; Zammit D; Camilleri DJ; Gatt A
J Clin Pathol; 2016 Jul; 69(7):637-42. PubMed ID: 26670745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
